Teva Pharmaceuticals
TEVA
450 hedge funds and large institutions have $4.12B invested in Teva Pharmaceuticals in 2021 Q4 according to their latest regulatory filings, with 77 funds opening new positions, 127 increasing their positions, 137 reducing their positions, and 51 closing their positions.
51% more first-time investments, than exits
New positions opened: 77 | Existing positions closed: 51
20% more funds holding in top 10
Funds holding in top 10: 5 → 6 (+1)
5% more funds holding
Funds holding: 429 → 450 (+21)
0.66% less ownership
Funds ownership: 47.85% → 47.19% (-0.66%)
7% less repeat investments, than reductions
Existing positions increased: 127 | Existing positions reduced: 137
9% less call options, than puts
Call options by funds: $345M | Put options by funds: $380M
20% less capital invested
Capital invested by funds: $5.14B → $4.12B (-$1.02B)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LIM
Lingotto Investment Management
London,
United Kingdom
|
+$135M |
| 2 |
Capital Research Global Investors
Los Angeles,
California
|
+$122M |
| 3 |
Group One Trading
Chicago,
Illinois
|
+$34.6M |
| 4 |
Citigroup
New York
|
+$32.7M |
| 5 |
MMH
Menora Mivtachim Holdings
Ramat Gan,
Israel
|
+$31M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Berkshire Hathaway
Omaha,
Nebraska
|
-$417M |
| 2 |
Capital World Investors
Los Angeles,
California
|
-$60.2M |
| 3 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
-$20.3M |
| 4 |
BMO
Beck Mack & Oliver
New York
|
-$16.9M |
| 5 |
IAM
Ion Asset Management
Herzliya,
Israel
|
-$15.9M |
TEVA Hedge Fund Activity: Q4 2021 in Review
450 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Teva Pharmaceuticals (TEVA) for Q4 2021, worth a combined $4.12B — down 20% from $5.14B a quarter earlier.
Buyers outnumbered sellers: 77 funds opened new TEVA positions and 51 closed out — a net gain of 26 holders — while 127 added to existing stakes and 137 trimmed.
The largest buyer was Lingotto Investment Management, opening a new position worth an estimated $135M. The largest seller was Berkshire Hathaway, exiting entirely with an estimated $417M sold.
- 450 institutional investors held Teva Pharmaceuticals (TEVA) as of Q4 2021, up from 429 in Q3 2021.
- Funds reported $4.12B of Teva Pharmaceuticals stock for Q4 2021, down 20% quarter-over-quarter.
- 77 funds opened new Teva Pharmaceuticals positions in Q4 2021 and 51 closed out, a net change of +26 holders.
- The largest Teva Pharmaceuticals buyer in Q4 2021 was Lingotto Investment Management, an estimated $135M added.
- The largest Teva Pharmaceuticals seller in Q4 2021 was Berkshire Hathaway, an estimated $417M sold.
Based on aggregated 13F filings for Q4 2021.